Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words 'Opal, SM' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 78 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Opal, SM; Sypek, JP; Keith, JC; Schaub, RG; Palardy, JE; Parejo, NA
      Evaluation of the safety of recombinant P-selectin glycoprotein ligand-immunoglobulin G fusion protein in experimental models of localized and systemic infection

      SHOCK
    2. Opal, SM; Palardy, JE; Parejo, N; Morrison, DC
      Lipopolyamines as a therapeutic strategy in experimental Gram-negative bacterial sepsis

      JOURNAL OF ENDOTOXIN RESEARCH
    3. Warren, BL; Eid, A; Singer, P; Pillay, SS; Carl, P; Novak, I; Chalupa, P; Atherstone, A; Penzes, I; Kubler, A; Knaub, S; Keinecke, HO; Heinrichs, H; Schindel, F; Juers, M; Bone, RC; Opal, SM
      High-dose a randomized antithrombin III in severe sepsis - A randomized controlled trial

      JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    4. Opal, SM; Palardy, JE; Parejo, NA; Creasey, AA
      The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis

      CRITICAL CARE MEDICINE
    5. Florquin, S; van den Berg, JG; Olszyna, DP; Claessen, N; Opal, SM; Weening, JJ; van der Poll, T
      Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia

      KIDNEY INTERNATIONAL
    6. Cross, AS; Opal, SM; Warren, HS; Palardy, JE; Glaser, K; Parejo, NA; Bhattacharjee, AK
      Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis

      JOURNAL OF INFECTIOUS DISEASES
    7. Opal, SM
      Protein C levels in severe sepsis

      CHEST
    8. Horn, DL; Morrison, DC; Opal, SM; Silverstein, R; Visvanathan, K; Zabriskie, JB
      What are the microbial components implicated in the pathogenesis of sepsis? Report on a symposium

      CLINICAL INFECTIOUS DISEASES
    9. Opal, SM; Huber, CE
      The role of interleukin-10 in critical illness

      CURRENT OPINION IN INFECTIOUS DISEASES
    10. Opal, SM
      The interaction between the coagulation system and the systemic inflammatory mediators

      IMMUNE RESPONSE IN THE CRITICALLY ILL
    11. Opal, SM
      Prospects for a vaccine to prevent bacterial sepsis

      IMMUNE RESPONSE IN THE CRITICALLY ILL
    12. Opal, SM
      Therapeutic rationale for antithrombin III in sepsis

      CRITICAL CARE MEDICINE
    13. Opal, SM
      Phylogenetic and functional relationships between coagulation and the innate immune response

      CRITICAL CARE MEDICINE
    14. Opal, SM
      Hemofiltration-absorption systems for the treatment of experimental sepsis: Is it possible to remove the "evil humors" responsible for septic shock?

      CRITICAL CARE MEDICINE
    15. Abraham, E; Matthay, MA; Dinarello, CA; Vincent, JL; Cohen, J; Opal, SM; Glauser, M; Parsons, P; Fisher, CJ; Repine, JE
      Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a reevaluation

      CRITICAL CARE MEDICINE
    16. Olszyna, DP; Opal, SM; Prins, JM; Horn, DL; Speelman, P; van Deventer, SJH; van der Poll, T
      Chemotactic activity of CXC chemokines interleukin-8, growth-related oncogene-alpha, and epithelial cell-derived neutrophil-activating protein-78 in urine of patients with urosepsis

      JOURNAL OF INFECTIOUS DISEASES
    17. Simpson, AJH; Opal, SM; Angus, BJ; Prins, JM; Palardy, JE; Parejo, NA; Chaowagul, W; White, NJ
      Differential antibiotic-induced endotoxin release in severe melioidosis

      JOURNAL OF INFECTIOUS DISEASES
    18. Opal, SM; Keith, JC; Palardy, JE; Parejo, N
      Recombinant human interleukin-11 has anti-inflammatory actions yet does not exacerbate systemic Listeria infection

      JOURNAL OF INFECTIOUS DISEASES
    19. Opal, SM; DePalo, VA
      Anti-inflammatory cytokines

      CHEST
    20. Opal, SM; Cross, AS
      Clinical trials for severe sepsis - Past failures, and future hopes

      INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
    21. Opal, SM; Cross, AS
      Bacterial sepsis and septic shock - Preface

      INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
    22. Cross, AS; Opal, SM; Bhattacharjee, AK; Donta, ST; Peduzzi, PN; Furer, E; Que, JU; Cryz, SJ
      Immunotherapy of sepsis: flawed concept or faulty implementation?

      VACCINE
    23. Opal, SM
      Selenium replacement in severe systemic inflammatory response syndrome

      CRITICAL CARE MEDICINE
    24. Opal, SM; Cohen, J
      Clinical Gram-positive sepsis: Does it fundamentally differ from Gram-negative bacterial sepsis?

      CRITICAL CARE MEDICINE
    25. Opal, SM
      Tumor necrosis factor receptor expression on inflammatory cells in sepsis

      CRITICAL CARE MEDICINE
    26. Opal, SM; Scannon, PJ; Vincent, JL; White, M; Carroll, SF; Palardy, JE; Parejo, NA; Pribble, JP; Lemke, JH
      Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock

      JOURNAL OF INFECTIOUS DISEASES
    27. Opal, SM; Jhung, JW; Keith, JC; Goldman, SJ; Palardy, JE; Parejo, NA
      Additive effects of human recombinant interleukin-11 and granulocyte colony-stimulating factor in experimental gram-negative sepsis

      BLOOD
    28. Opal, SM
      The value of animal models in endotoxin research

      ENDOTOXIN IN HEALTH AND DISEASE
    29. Brade, H; Opal, SM; Vogel, SN; Morrison, DC
      The future of endotoxin research

      ENDOTOXIN IN HEALTH AND DISEASE
    30. OPAL SM
      PHARMACOKINETICS OF A RECOMBINANT AMINO-TERMINAL FRAGMENT OF BACTERICIDAL PERMEABILITY-INCREASING PROTEIN (RBPI(21)) AFTER LIVER SURGERY INRATS AND HUMANS - EDITORIAL COMMENT

      Shock
    31. HORN DL; ZABRISKIE JB; AUSTRIAN R; CLEARY PP; FERRETTI JJ; FISCHETTI VA; GOTSCHLICH E; KAPLAN EL; MCCARTY M; OPAL SM; ROBERTS RB; TOMASZ A; WACHTFOGEL Y
      WHY HAVE GROUP-A STREPTOCOCCI REMAINED SUSCEPTIBLE TO PENICILLIN - REPORT ON A SYMPOSIUM

      Clinical infectious diseases
    32. Opal, SM; Wherry, JC; Grint, P
      Interleukin-10: Potential benefits and possible risks in clinical infectious diseases

      CLINICAL INFECTIOUS DISEASES
    33. OPAL SM; JHUNG JW; KEITH JC; PALARDY JE; PAREJO NA; YOUNG LD; BHATTACHARJEE A
      RECOMBINANT HUMAN INTERLEUKIN-LL IN EXPERIMENTAL PSEUDOMONAS-AERUGINOSA SEPSIS IN IMMUNOCOMPROMISED ANIMALS

      The Journal of infectious diseases
    34. OPAL SM; YU RL
      ANTIENDOTOXIN STRATEGIES FOR THE PREVENTION AND TREATMENT OF SEPTIC SHOCK - NEW APPROACHES AND FUTURE-DIRECTIONS

      Drugs
    35. OPAL SM
      THE UNCERTAIN VALUE OF THE DEFINITION FOR SIRS

      Chest
    36. OPAL SM; FISHER CJ; DHAINAUT JFA; VINCENT JL; BRASE R; LOWRY SF; SADOFF JC; SLOTMAN GJ; LEVY H; BALK RA; SHELLY MP; PRIBBLE JP; LABRECQUE JF; LOOKABAUGH J; DONOVAN H; DUBIN H; BAUGHMAN R; NORMAN J; DEMARIA E; MATZEL K; ABRAHAM E; SENEFF M; BARBER A; BRAYMAN K; CERRA F; CHALFIN D; CHAZEN G; CHRISTOU N; COONEY R; CORBIN R; DREW R; EMMANUEL G; PINES B; ERON L; FLETCHER R; FOULKE G; GALLAGHER T; GERVICH D; GROSSMAN J; HALPERN N; HANNA C; JOHNSON S; KUBAK B; LODATO R; LOVETT M; MARSHALL J; METZLER M; NELSON L; FREELAND M; OROPELLO J; PAZ H; RACKOW E; RIKER R; RISSING P; SCHEIN R; SCHELD M; SCHUSTER D; SIBBALD W; SILVERMAN H; SOMERMEYER M; STRANGE C; SUMMER W; TOPIEL M; WHITE J; ALESTIG K; ANDERSEN PK; ANDERSSON J; BENNETT D; BERG S; BLEICHNER G; BRUNET F; CARLET J; DEJONG MJ; DREXLER H; GARRARD C; HESLET L; KLOSS T; PAUL W; REINHART K; RENAUD B; RITZ R; ROMME JH; SCHMITZ JE; STOCKENHUBER F; SUTER P; TENAILLON A; VAGT A; VANDERMEER WM; VANDEVENTER S; VANLEEUWEN PAM; VERHOEF J; WEBSTER N; WINTER RJ; WOLFF M; STILES DM; DEVOS A; CROFT C; FAZIO J; THOMPSON R; WIEDEMANN H; ELLISON RT; CHINCHILLI VM; YARBOROUGH M
      CONFIRMATORY INTERLEUKIN-1 RECEPTOR ANTAGONIST TRIAL IN SEVERE SEPSIS- A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL

      Critical care medicine
    37. ORANGE JS; SALAZARMATHER TP; OPAL SM; BIRON CA
      MECHANISMS FOR VIRUS-INDUCED LIVER-DISEASE - TUMOR NECROSIS FACTOR-MEDIATED PATHOLOGY INDEPENDENT OF NATURAL-KILLER AND T-CELLS DURING MURINE CYTOMEGALOVIRUS-INFECTION

      Journal of virology
    38. RUZEK MC; MILLER AH; OPAL SM; PEARCE BD; BIRON CA
      CHARACTERIZATION OF EARLY CYTOKINE RESPONSES AND AN INTERLEUKIN (IL)-6-DEPENDENT PATHWAY OF ENDOGENOUS GLUCOCORTICOID INDUCTION DURING MURINE CYTOMEGALOVIRUS-INFECTION

      The Journal of experimental medicine
    39. DELLINGER RP; OPAL SM; ROTROSEN D; SUFFREDINI AF; ZIMMERMAN JL; BONE RC; BOSKEN CH; DELLINGER P; GOLDSTEIN RA; HURD S; VINCENT JL; ABRAHAM E; ADAMS HR; ARTIGAS A; BALK RA; BERNARD GR; BEUTLER B; COHEN J; COOK DJ; DANNER RL; DORINSKI PM; FISHER CJ; FINK MP; GLAUSER MP; HARKINS R; LAUCHENBRUCH P; MUNFORD RS; NATANSON C; NELSON S; PARRILLO JE; PENNINGTON JE; ROBERTS R; SIBBALD WJ; SIEGEL JN; STRAUBE RC; TERES D; ULEVITCH RJ; VOGEL S; WARREN S; WRIGHT SD
      FROM THE BENCH TO THE BEDSIDE - THE FUTURE OF SEPSIS RESEARCH

      Chest
    40. HORN DL; HEWLETT D; ALFALLA C; PATEL A; BRUDNEY K; CRAWFORD JT; ALLAND D; KREISWIRTH B; OPAL SM; PETERSON S
      CLINICAL-EXPERIENCE WITH RIFAMPIN-ISONIAZID-STREPTOMYCIN-ETHAMBUTOL (RISE)-RESISTANT TUBERCULOSIS

      Infectious diseases in clinical practice
    41. OPAL SM; HORN DL; PALARDY JE; PAREJO N; JHUNG J; BHATTACHARJEE A; YOUNG LD
      THE IN-VIVO SIGNIFICANCE OF ANTIBIOTIC-INDUCED ENDOTOXIN RELEASE IN EXPERIMENTAL GRAM-NEGATIVE SEPSIS

      Journal of endotoxin research
    42. KNAUS WA; HARRELL FE; LABRECQUE JF; WAGNER DP; PRIBBLE JP; DRAPER EA; FISHER CJ; SOLL L; ASTIZ M; RACKOW EC; CARPATI C; BALK RA; FRIEDMAN B; MURE AJ; SHAPIRO E; MELHOM L; SHAPIRO MJ; TAYLOR R; KEEGAN M; OBRIEN J; GREENMAN RL; SCHEIN R; PENA M; WASSERLOUF M; IBERTI TJ; OROPELLO J; BENJAMIN E; DELGUIDICE R; EMMANUEL G; LIE T; ANDERSON L; MARSHALL J; DEMAJO W; ROTSTEIN O; FOSTER D; ABRAHAM E; MIDDLETON H; PERRY C; LEVY H; FRY DE; SIMPSON SQ; CROWELL RE; NEIDHART M; STEVENS D; COFFMAN T; NARASIMHAN N; MERRICK DK; BERQUIST W; MATZEL K; HUEBLER M; FOULKE G; ALBERTSON T; WALBY W; ALLEN R; BAUGHMAN R; HASSELGREN PO; FINK MP; FAVORITO F; THOMAS BT; CORBIN R; SHELLHORSE GY; FRAZIER A; WHITE S; GARRARD C; ACOURT C; GERVICH D; BRASE R; BAGDAHN A; COONEY R; SMITH JS; VINCENT JL; FRIEDMAN G; BERLOT G; FLETCHER JR; WILLIAMS MD; WRIGHT TF; JOHNSON S; FEILD C; WOLF K; MACINTYRE N; DUBIN H; DURKIN M; STAUBACH KH; FEIN AM; SCHULMAN DB; NIEDERMAN MS; CHALFIN DB; VANLEEUVEN PAM; BANDER J; IMM A; BERNARD G; NELSON L; STROUD M; SAFCSAK K; CERRA F; RINDAL J; MANN H; HALPERN N; ALICEA M; SIBBALD WJ; MARTIN CM; RUTLEDGE FS; PETTI K; RUSSELL J; KRUGER R; DRUMMOND A; FISHER CS; LANGE P; SELFERT T; DUROCHER A; TENAILLON A; BOITEAU R; LHERM T; LOWRY S; COYLE SM; BARIE PS; DEMARIA E; REINES HD; SNYDMAN D; SCHWAITZBERG S; NASRAWAY S; GRINDLINGER J; SUMMER W; DEBOISBLANC B; WAHL M; ALESTIG K; GROSSMAN J; MAKI D; PAZ HL; WEINER M; BIHARI D; BLEICHNER G; DAHN M; HALL J; WENZEL RP; GROSSERODE M; COSTIGAN M; MILESKI W; WEIGELT J; YESTON N; IRIZARRY C; ROSS J; ROBBINS J; SHELLY MP; NIGHTINGALE P; OWEN K; SANDSTEDT S; BERG S; SIMON G; SENEFF M; CONRY K; ZIMMERMAN JL; DELLINGER RP; JOHNSTON R; ALLEE P; GRANDE PO; MYHRE E; DHAINAUT JF; HAMY I; MIRA JP; HARMON J; WHITE J; MCKIE L; SILVERMAN H; TUMA P; BENNETT D; LAURELL MH; JACOBS S; ASH S; OPAL SM; SLOTMAN GJ; IBERTI TJ; SADOFF JC; STILES DM; THOMPSON B; PRIOR MJ; KNATTERUD G; TERRIN M; KUFERA J; WILKENS P; RA K; MONROE L; SPRUNG C; HAMILTON CM; MATTHAY R; MCCABE W; TONASCIA J; WIEDMAN H; WITTES J; THOMPSON BW; LABRECQUE JF; CATALANO MA; CAMPION GV; CROFT CR; LUSTICK R; LOOKABAUGH J; GORDON GS; NOE L; BLOEDOW D; SMITH CG; BRANNON D; KUSH R; NG D; MOORE E; BAZEMORE K; GALVAN M; WAGNER D; HARRELL F; STABLEIN D
      USE OF PREDICTED RISK OF MORTALITY TO EVALUATE THE EFFICACY OF ANTICYTOKINE THERAPY IN SEPSIS

      Critical care medicine
    43. HORN DL; OPAL SM; LOMASTRO E
      ANTIBIOTICS, CYTOKINES, AND ENDOTOXIN - A COMPLEX AND EVOLVING RELATIONSHIP IN GRAM-NEGATIVE SEPSIS

      Scandinavian journal of infectious diseases
    44. FISHER CJ; AGOSTI JM; OPAL SM
      TUMOR-NECROSIS-FACTOR RECEPTOR-FC FUSION PROTEIN IN SEPTIC SHOCK - REPLY

      The New England journal of medicine
    45. FISHER CJ; AGOSTI JM; OPAL SM; LOWRY SF; BALK RA; SADOFF JC; ABRAHAM E; SCHEIN RMH; BENJAMIN E
      TREATMENT OF SEPTIC SHOCK WITH THE TUMOR-NECROSIS-FACTOR RECEPTOR-FC FUSION PROTEIN

      The New England journal of medicine
    46. OPAL SM; CROSS AS; JHUNG JW; YOUNG LD; PALARDY JE; PAREJO NA; DONSKY C
      POTENTIAL HAZARDS OF COMBINATION IMMUNOTHERAPY IN THE TREATMENT OF EXPERIMENTAL SEPTIC SHOCK

      The Journal of infectious diseases
    47. BHATTACHARJEE AK; OPAL SM; TAYLOR R; NASO R; SEMENUK M; ZOLLINGER WD; MORAN EE; YOUNG L; HAMMACK C; SADOFF JC; CROSS AS
      A NONCOVALENT COMPLEX VACCINE PREPARED WITH DETOXIFIED ESCHERICHIA-COLI J5 (RC CHEMOTYPE) LIPOPOLYSACCHARIDE AND NEISSERIA-MENINGITIDIS GROUP-B OUTER-MEMBRANE PROTEIN PRODUCES PROTECTIVE ANTIBODIES AGAINST GRAM-NEGATIVE BACTEREMIA

      The Journal of infectious diseases
    48. RICE SK; HEINL RE; THORNTON LL; OPAL SM
      CLINICAL CHARACTERISTICS, MANAGEMENT STRATEGIES, AND COST IMPLICATIONS OF A STATEWIDE OUTBREAK OF ENTEROVIRUS MENINGITIS

      Clinical infectious diseases
    49. MEYERHOFF A; RENZI RM; WEHBE T; OPAL SM
      FATAL CLOSTRIDIAL SEPSIS IN A PREVIOUSLY HEALTHY WOMAN

      Clinical infectious diseases
    50. HEWLETT D; HORN DL; FRANCHINI D; ALFALLA C; PETERSON S; PELLA P; OPAL SM
      NOSOCOMIAL INFECTION WITH MULTIDRUG-RESISTANT AND MULTIDRUG-SUSCEPTIBLE TUBERCULOSIS IN 91 HEALTH-CARE WORKERS

      Infectious diseases in clinical practice
    51. HORN DL; HEWLETT D; ALFALLA C; PELLA P; FRANCHINI D; PETERSON S; OPAL SM
      LIMITED TOLERANCE OF OF OFLOXACIN AND PYRAZINAMIDE PROPHYLAXIS IN HEALTH-CARE WORKERS FOLLOWING EXPOSURE TO FAMPIN-ISONIAZID-STREPTOMYCIN-ETHAMBUTOL-RESISTANT TUBERCULOSIS

      Infectious diseases in clinical practice
    52. CROSS AS; OPAL SM
      ENDOTOXINS ROLE IN GRAM-NEGATIVE BACTERIAL-INFECTION

      Current opinion in infectious diseases
    53. ORANGE JS; SALAZARMATHER TP; OPAL SM; SPENCER RL; MILLER AH; MCEWEN BS; BIRON CA
      ROLE OF TNF IN IL-12-INDUCED TOXICITIES DURING VIRAL-INFECTION

      Journal of cellular biochemistry
    54. OPAL SM; PALARDY JE; JHUNG JW; DONSKY C; ROMULO RLC; PAREJO N; MARRA MN
      ACTIVITY OF LIPOPOLYSACCHARIDE-BINDING PROTEIN-BACTERICIDAL PERMEABILITY-INCREASING PROTEIN FUSION PEPTIDE IN AN EXPERIMENTAL-MODEL OF PSEUDOMONAS SEPSIS

      Antimicrobial agents and chemotherapy
    55. ORANGE JS; SALAZARMATHER TP; OPAL SM; SPENCER RL; MILLER AH; MCEWEN BS; BIRON CA
      MECHANISM OF INTERLEUKIN 12-MEDIATED TOXICITIES DURING EXPERIMENTAL VIRAL-INFECTIONS - ROLE OF TUMOR-NECROSIS-FACTOR AND GLUCOCORTICOIDS

      The Journal of experimental medicine
    56. OPAL SM; KEITH JC; SCHAUB RG; PALARDY J; PAREJO N; JHUNG J; BHATTACHARJEE A; YOUNG L
      BENEFICIAL-EFFECTS OF RECOMBINANT HUMAN INTERLEUKIN-11 (RHIL-11) IN AN EXPERIMENTAL-MODEL OF GRAM-NEGATIVE SEPSIS IN NEUTROPENIC ANIMALS

      Blood
    57. CORONADO BE; OPAL SM; YOBURN DC
      ANTIBIOTIC-INDUCED D-LACTIC ACIDOSIS

      Annals of internal medicine
    58. ORANGE JS; SALAZARMATHER T; OPAL SM; BIRON CA
      TNF EXPRESSION AND FUNCTION DURING PROTECTIVE IMMUNE-RESPONSES TO VIRAL-INFECTION

      The FASEB journal
    59. POLOLI LH; COLETTA EM; KERN DG; DAVIS S; KIESSLING LS; GARBER CE; ENTIN EJ; OPAL SM; RAKOWSKI W
      DEVELOPING A COMPETENCE-BASED PREVENTIVE MEDICINE CURRICULUM FOR MEDICAL-SCHOOLS

      American journal of preventive medicine
    60. OPAL SM; PALARDY JE; MARRA MN; FISHER CJ; MCKELLIGON BM; SCOTT RW
      RELATIVE CONCENTRATIONS OF ENDOTOXIN-BINDING PROTEINS IN BODY-FLUIDS DURING INFECTION

      Lancet
    61. FISHER CJ; DHAINAUT JFA; OPAL SM; PRIBBLE JP; BALK RA; SLOTMAN GJ; IBERTI TJ; RACKOW EC; SHAPIRO MJ; GREENMAN RL; REINES HD; SHELLY MP; THOMPSON BW; LABRECQUE JF; CATALANO MA; KNAUS WA; SADOFF JC
      RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF PATIENTS WITH SEPSIS SYNDROME (VOL 271, PG 1836, 1994)

      JAMA, the journal of the American Medical Association
    62. FISHER CJ; DHAINAUT JFA; OPAL SM; PRIBBLE JP; BALK RA; SLOTMAN GJ; IBERTI TJ; RACKOW EC; SHAPIRO MJ; GREENMAN RL; REINES HD; SHELLY MP; THOMPSON BW; LABRECQUE JF; CATALANO MA; KNAUS WA; SADOFF JC; ASTIZ M; CARPATI C; BONE RC; FREIDMAN B; MURE AJ; BRATHWAITE C; SHAPIRO E; MELHORN L; TAYLOR R; KEEGAN M; OBRIEN J; SCHEIN R; PENA M; WASSERLOUF M; OROPELLO J; BENJAMIN E; DELGUIDICE R; EMMANUEL G; LIE T; ANDERSON L; MARSHALL J; DEMAJO W; ROTSTEIN O; FOSTER D; ABRAHAM E; MIDDLETON H; PERRY C; LEVY H; FRY DE; SIMPSON SQ; CROWELL RE; NEIDHART M; STEVENS D; COFFMAN T; NARASIMHAM N; MERRICK DK; BERGQUIST W; MATZEL KE; HUEBLER M; FOULKE GE; ALBERTSON TE; WALBY WF; ALLEN RP; BAUGHMAN R; HASSELGREN PO; FINK MP; FAVORITO F; THOMPSON BT; CORBIN R; SHELLHORSE GY; FRAZIER A; WHITE S; GARRARD C; ACOURT C; STORER S; GERVICH DH; FOSHE D; BRASE R; BAGDAHN A; COONEY R; SMITH JS; MARTIN LF; VINCENT JL; FRIEDMAN G; BERLOT G; FLETCHER JR; WILLIAMS MD; WRIGHT TF; JOHNSON S; FEILD C; WOLF K; MACINTYRE N; DUBIN HG; DURKIN MR; DUBIN PK; STAUBACH KH; FEIN AM; SCHULMAN DB; NIEDERMAN MS; CHALFIN DB; VANLEEUWEN PAM; BOERMEESTER MA; SCHNEIDER AJ; BANDER J; IMM A; BERNARD G; NELSON L; STROUD M; SAFCSAK K; CERRA F; RINDAL J; MANN H; HALPERN N; SILVERSTEIN J; ALICEA M; SIBBALD WJ; MARTIN CM; RUTLEDGE FS; PETTI K; RUSSELL JA; KRUGER R; DRUMMOND A; LANGE P; SEIFERT T; DUROCHER A; TENAILLON A; BOITEAU R; LHERM T; LOWRY SF; COYLE SM; BARIE PS; DEMARIA E; SNYDMAN DR; SCHWAITZBERG SD; NASRAWAY SA; GRINDLINGER J; SUMMER W; DEBOISBLANC B; WAHL M; ALESTIG K; GROSSMAN J; MAKI D; PAZ HL; WEINER M; BIHARI D; CAMPBELL D; BLEICHNER G; DAHN MS; LANGE MPA; HALL J; POHLMAN A; WENZEL RP; GROSSERODE M; COSTIGAN M; MILESKI W; WEIGELT J; YESTON N; IRIZARRY C; ROSS J; ROBBINS J; NIGHTINGALE P; OWEN K; SANDSTEDT S; BERG S; SIMON GL; SENEFF MG; CONRY KM; ZIMMERMAN JL; DELLINGER RP; JOHNSTON R; ALLEE P; GRANDE PO; MYHRE E; DHAINAUT JF; HAMY I; MIRA JP; HARMON J; WHITE J; MCKIE L; SILVERMAN H; TUMA P; BENNETT D; PORTER JC; LAURELL MH; JACOBS S; ASH S; STILES DM; PRIOR MJ; KNATTERUD G; TERRIN M; KUFERA J; WILKENS P; RA K; MONROE L; SPRUNG C; HAMILTON CM; MATTHAY R; MCCABE W; TONASCIA J; WIEDEMAN H; WITTES J; CAMPION GV; CROFT CR; LUSTICK R; LOOKABAUGH J; GORDON GS; NOE L; BLOEDOW D; SMITH CG; BRANNON D; KUSH R; NG D; MOORE E; BAZEMORE K; GALVAN M; WAGNER D; HARRELL F; STABLEIN D
      RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF PATIENTS WITH SEPSIS SYNDROME - RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

      JAMA, the journal of the American Medical Association
    63. BOYCE JM; OPAL SM; CHOW JW; ZERVOS MJ; POTTERBYNOE G; SHERMAN CB; ROMULO RLC; FORTNA S; MEDEIROS AA
      OUTBREAK OF MULTIDRUG-RESISTANT ENTEROCOCCUS-FAECIUM WITH TRANSFERABLE VANB CLASS VANCOMYCIN RESISTANCE

      Journal of clinical microbiology
    64. FISHER CJ; OPAL SM; LOWRY SF; SADOFF JC; LABRECQUE JF; DONOVAN HC; LOOKABAUGH JL; LEMKE J; PRIBBLE JP; STROMATT SC; VIGERS GP; RUSSELL DA; THOMPSON RC
      ROLE OF INTERLEUKIN-1 AND THE THERAPEUTIC POTENTIAL OF INTERLEUKIN-1 RECEPTOR ANTAGONIST IN SEPSIS

      Circulatory shock
    65. FISHER CJ; MARRA MN; PALARDY JE; MARCHBANKS CR; SCOTT RW; OPAL SM
      HUMAN NEUTROPHIL BACTERICIDAL PERMEABILITY-INCREASING PROTEIN REDUCESMORTALITY-RATE FROM ENDOTOXIN CHALLENGE - A PLACEBO-CONTROLLED STUDY

      Critical care medicine
    66. FISHER CJ; OPAL SM
      TUMOR-NECROSIS-FACTOR IN CRITICAL ILLNESS - REPLY

      Critical care medicine
    67. FISHER CJ; SLOTMAN GJ; OPAL SM; PRIBBLE JP; BONE RC; EMMANUEL G; NG D; BLOEDOW DC; CATALANO MA; FRIEDMAN B; MURE A; SHAPIRO E
      INITIAL EVALUATION OF HUMAN RECOMBINANT INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF SEPSIS SYNDROME - A RANDOMIZED, OPEN-LABEL, PLACEBO-CONTROLLED MULTICENTER TRIAL

      Critical care medicine
    68. HORN DL; HEWLETT D; ALFALLA C; PETERSON S; OPAL SM
      LIMITED TOLERANCE OF OFLOXACIN AND PYRAZINAMIDE PROPHYLAXIS AGAINST TUBERCULOSIS

      The New England journal of medicine
    69. BHATTACHARJEE AK; OPAL SM; PALARDY JE; DRABICK JJ; COLLINS H; TAYLOR R; COTTON A; CROSS AS
      AFFINITY-PURIFIED ESCHERICHIA-COLI J5 LIPOPOLYSACCHARIDE-SPECIFIC IGGPROTECTS NEUTROPENIC RATS AGAINST GRAM-NEGATIVE BACTERIAL SEPSIS

      The Journal of infectious diseases
    70. SUITTERS AJ; FOULKES R; OPAL SM; PALARDY JE; EMTAGE JS; ROLFE M; STEPHENS S; MORGAN A; HOLT AR; CHAPLIN LC; SHAW NE; NESBITT AM; BODMER MW
      DIFFERENTIAL EFFECT OF ISOTYPE ON EFFICACY OF ANTITUMOR NECROSIS FACTOR-ALPHA CHIMERIC ANTIBODIES IN EXPERIMENTAL SEPTIC SHOCK

      The Journal of experimental medicine
    71. MARRA MN; SCOTT RW; MCKELLIGON BM; OPAL SM
      BACTERICIDAL PERMEABILITY-INCREASING PROTEIN (BPI) LEVELS EXCEED LIPOPOLYSACCHARIDE-BINDING PROTEIN (LBP) IN FLUIDS AT INFECTED SITES

      Clinical research
    72. HORN DL; HEWLETT D; HAAS WH; BUTLER WR; ALFALLA C; TAN E; LEVINE A; NAYAK A; OPAL SM
      SUPERINFECTION WITH RIFAMPIN-ISONIAZID-STREPTOMYCIN-ETHAMBUTOL (RISE)-RESISTANT TUBERCULOSIS IN 3 PATIENTS WITH AIDS - CONFIRMATION BY POLYMERASE CHAIN-REACTION FINGERPRINTING

      Annals of internal medicine
    73. BOYCE JM; OPAL SM; POTTERBYNOE G; MEDEIROS AA
      SPREAD OF METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS IN A HOSPITAL AFTER EXPOSURE TO A HEALTH-CARE WORKER WITH CHRONIC SINUSITIS

      Clinical infectious diseases
    74. KNAUS WA; HARRELL FE; FISHER CJ; WAGNER DP; OPAL SM; SADOFF JC; DRAPER EA; WALAWANDER CA; CONBOY K; GRASELA TH
      THE CLINICAL-EVALUATION OF NEW DRUGS FOR SEPSIS - A PROSPECTIVE-STUDYDESIGN BASED ON SURVIVAL ANALYSIS

      JAMA, the journal of the American Medical Association
    75. RICHARDS MS; RITTMAN M; GILBERT TT; OPAL SM; DEBUONO BA; NEILL RJ; GEMSKI P
      INVESTIGATION OF A STAPHYLOCOCCAL FOOD POISONING OUTBREAK IN A CENTRALIZED SCHOOL LUNCH PROGRAM

      Public health reports
    76. CROSS AS; OPAL SM; SADOFF JC; GEMSKI P
      CHOICE OF BACTERIA IN ANIMAL-MODELS OF SEPSIS

      Infection and immunity
    77. LANORE JJ; DHAINAUT JF; FISHER CJ; OPAL SM; ZIMMERMAN J; NIGHTINGALE P; STEPHENS S; SCHEIN RL; PANACEK EA; VINCENT JL; FOULKE GE; WARREN EL; GARRARD C; PARK G; BODMER MW; COHEN J; VANDERLINDEN G; SADOFF JC; POCHARD F
      EFFECTS OF AN ANTI-TNF IGG MONOCLONAL-ANTIBODY ON LEFT-VENTRICULAR PERFORMANCE IN SEPTIC PATIENTS

      The American review of respiratory disease
    78. KIM KS; WASS CA; CROSS AS; OPAL SM
      MODULATION OF BLOOD-BRAIN-BARRIER PERMEABILITY BY TUMOR-NECROSIS-FACTOR AND ANTIBODY TO TUMOR-NECROSIS-FACTOR IN THE RAT

      Lymphokine and cytokine research


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/06/20 alle ore 06:12:19